Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTA Stock Price Chart Interactive Chart >
MGTA Price/Volume Stats
|Current price||$7.79||52-week high||$14.20|
|Prev. close||$6.87||52-week low||$5.89|
|Day high||$7.86||Avg. volume||260,054|
|50-day MA||$7.04||Dividend yield||N/A|
|200-day MA||$9.61||Market Cap||456.24M|
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
MGTA Latest News Stream
|Loading, please wait...|
MGTA Latest Social Stream
View Full MGTA Social Stream
Latest MGTA News From Around the Web
Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...
CAMBRIDGE, Mass., August 05, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the second quarter ended June 30, 2021, and recent program highlights.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
CAMBRIDGE, Mass., August 03, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
No summary available.
MGTA Price Returns